Is Rein Therapeutics, Inc. Common Stock profitable?

Rein Therapeutics, Inc. Common Stock is not currently profitable: it reported a net loss of $50.2M over the trailing twelve months.

What is Rein Therapeutics, Inc. Common Stock's earnings per share?

Rein Therapeutics, Inc. Common Stock's diluted EPS over the trailing twelve months is $-1.90.

Where does Rein Therapeutics, Inc. Common Stock's income statement data come from?

Every line is extracted from Rein Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Rein Therapeutics, Inc. Common Stock RNTX Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Total revenue	$0—	$0—	$0—	$0—	$0—
Research and development	$11.05M+0.2%	$11.03M-10.7%	$12.35M-14.2%	$14.39M+4.0%	$13.84M-2.9%
General and administrative	$10.51M-3.7%	$10.9M-4.5%	$11.42M+14.7%	$9.96M-21.4%	$12.68M-8.6%
Restructuring charges	——	——	——	——	——
Impairment charges	——	$28.7M-6.7%	$30.78M-6.3%	$32.85M-5.9%	$34.93M-5.6%
Other operating expenses	$50.25M-0.7%	$50.63M-16.7%	$60.77M-0.9%	$61.35M-3.4%	$63.52M-2.5%
Total operating expenses	$50.25M-0.7%	$50.63M-16.7%	$60.77M-0.9%	$61.35M-3.4%	$63.52M-2.5%
Operating income	-$50.25M+0.7%	-$50.63M+16.7%	-$60.77M+0.9%	-$61.35M+3.4%	-$63.52M+2.5%
Other income (expense), net	——	——	$340K-47.9%	$653K-6.8%	$701K+2.3%
Income tax expense	——	-$712K+22.6%	-$920K+18.4%	-$1.13M+15.6%	-$1.34M+13.5%
Net income	-$50.21M-0.7%	-$49.87M+15.3%	-$58.89M+0.4%	-$59.15M+3.5%	-$61.27M+2.6%
Diluted earnings per share	-$1.90+3.1%	-$1.96+33.3%	-$2.94+2.0%	-$3.00+5.4%	-$3.17+16.1%
Basic earnings per share	-$1.90+3.1%	-$1.96+33.3%	-$2.94+2.0%	-$3.00+5.4%	-$3.17+16.1%
Weighted-average shares, diluted	106.3M+8.6%	97.9M+8.3%	90.4M+5.5%	85.7M+5.3%	81.4M+20.1%
Weighted-average shares, basic	106.3M+8.6%	97.9M+8.3%	90.4M+5.5%	85.7M+5.3%	81.4M+20.1%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	-$50.24M-0.6%	-$49.92M+15.3%	-$58.9M+0.5%	-$59.17M+3.4%	-$61.24M+2.5%
Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax	-$60K-107%	-$29K-514%	$7K0.0%	$7K-77.4%	$31K—
Net unrealized gains (losses) on securities still held	——	——	-$25K+13.8%	-$29K—	$0-100%
Other income, net (Note 6)	——	——	$340K-47.9%	$653K-6.8%	$701K+2.3%
Revenue From Contract With Customer Excluding Assessed Tax	$0—	$0—	$0—	$0—	$0—
EBIT	-$50.25M+0.7%	-$50.63M+16.7%	-$60.77M+0.9%	-$61.35M+3.4%	-$63.52M+2.5%
EBITDA	——	——	——	——	——
EBIT	-$50.25M+0.7%	-$50.63M+16.7%	-$60.77M+0.9%	-$61.35M+3.4%	-$63.52M+2.5%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Is Rein Therapeutics, Inc. Common Stock profitable?: Rein Therapeutics, Inc. Common Stock is not currently profitable: it reported a net loss of $50.2M over the trailing twelve months.
What is Rein Therapeutics, Inc. Common Stock's earnings per share?: Rein Therapeutics, Inc. Common Stock's diluted EPS over the trailing twelve months is $-1.90.
Where does Rein Therapeutics, Inc. Common Stock's income statement data come from?: Every line is extracted from Rein Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.